An additional ramification of the current results may be in the area of cancer biology, where there has been interest in the potential use of GLO-1 inhibitors to target metabolic vulnerabilities of cancer cells (Gaffney et al., 2020; Rabbani et al., 2018). Here, GLO1 is linked to cancer.